Finder

Specialises in

• Breast

• Lung

Offers

• Face-to-face consultations
• Video and telephone consultations
• Home chemotherapy

About me

Dr Maher Hadaki is a UK-trained Consultant Clinical Oncologist specialising in the treatment of breast and lung cancers. He completed his specialist oncology training at Cambridge University Hospitals and University College London Hospital, and has been working as a consultant since 2012.

He provides comprehensive cancer care using chemotherapy, immunotherapy, hormone therapy, and radiotherapy, with treatments tailored to each patient's diagnosis, overall health, and personal priorities. Dr Hadaki has extensive experience in modern radiotherapy techniques, including IMRT and stereotactic body radiotherapy (SABR), allowing highly precise treatment while minimising side effects.

Alongside his private practice, Dr Hadaki holds an NHS consultant post at the Kent Oncology Centre, Maidstone Hospital, where he is an active member of the breast and lung multidisciplinary teams. He is a Fellow of the Royal College of Radiologists and a Member of the Royal College of Physicians.

Dr Hadaki is part of Bupa's Cancer Direct Access Service, enabling eligible patients to access specialist assessment promptly without a GP referral.

His clinical interests include early and advanced breast cancer, triple-negative breast cancer, non-small cell and small cell lung cancer, and the integration of systemic therapies with precision radiotherapy. His research interests focus on improving treatment outcomes while reducing toxicity and treatment burden.

Dr Hadaki places strong emphasis on clear communication, shared decision-making, and compassionate care, ensuring patients and their families feel informed and supported throughout treatment. Outside work, he values maintaining a healthy work-life balance, keeping active, and spending time with his family.

He also offers free educational talks for GPs, covering breast and lung cancer referral pathways, modern cancer treatments, radiotherapy indications, and the management of treatment side effects in the community.

Areas of interest

Breast cancer;
Early and locally advanced breast cancer;
Metastatic breast cancer;
Triple-negative breast cancer;
Lung cancer;
Non-small cell lung cancer;
Small cell lung cancer;
Chemotherapy;
Immunotherapy;
Hormone therapy;
Precision radiotherapy (IMRT);
Stereotactic body radiotherapy (SBRT/SABR)

Medical secretaries

• Alison Routledge
• 07491 268769
• mhadaki@nhs.net